{"id":558437,"date":"2021-08-18T13:04:02","date_gmt":"2021-08-18T13:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=558437"},"modified":"2021-08-18T13:04:02","modified_gmt":"2021-08-18T13:04:02","slug":"emerging-therapies-such-as-plxpad-pluristem-fgf1-venturis-therapeutics-inc-and-others-expected-to-positively-impact-the-intermittent-claudication-market-scenario-in-the-upcoming-years","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/emerging-therapies-such-as-plxpad-pluristem-fgf1-venturis-therapeutics-inc-and-others-expected-to-positively-impact-the-intermittent-claudication-market-scenario-in-the-upcoming-years_558437.html","title":{"rendered":"Emerging Therapies such as PLX-PAD (Pluristem), FGF-1 (Venturis Therapeutics, Inc.), and others Expected to Positively Impact the Intermittent Claudication Market Scenario in the Upcoming Years"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1629257760.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Emerging Therapies such as PLX-PAD (Pluristem), FGF-1 (Venturis Therapeutics, Inc.), and others Expected to Positively Impact the Intermittent Claudication Market Scenario in the Upcoming Years\" src=\"https:\/\/www.abnewswire.com\/uploads\/1629257760.png\" alt=\"Emerging Therapies such as PLX-PAD (Pluristem), FGF-1 (Venturis Therapeutics, Inc.), and others Expected to Positively Impact the Intermittent Claudication Market Scenario in the Upcoming Years\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Intermittent Claudication Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">An increase in the prevalence of Intermittent Claudication and the high demand for therapies, approval of emerging therapies such as PLX-PAD, FGF-1, and others will significantly boost the Intermittent Claudication therapy market size in the forecasted period (2021-2030).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/d05104cfc6fdc9572930cc095e42a950.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&rsquo;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intermittent-claudication-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Intermittent Claudication market report<\/a><\/strong><span> offers comprehensive coverage of the current treatment practices, emerging drugs, individual Intermittent Claudication therapy market share, and current and forecasted Intermittent Claudication market size from 2018 to 2030, segmented into 7MM (<\/span><span>the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Intermittent Claudication Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the American College of Cardiology (2020), Peripheral Artery Disease affects <\/span><strong>8.5 million<\/strong><span> people in the United States and becomes more common with age.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>According to the review article &ldquo;Intermittent Claudication&rdquo; by Patel et al. (2021), between <\/span><strong>10% and 35%<\/strong><span> of all patients with the peripheral arterial disease will have a presentation of &ldquo;classic&rdquo; Intermittent Claudication.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Various key players such as<\/span><span>&nbsp;<\/span><strong>Venturis Therapeutics, Inc., Pluristem, <\/strong><span>and others are in the process of developing potential therapies for Intermittent Claudication treatment.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Pluristem&#8217;s PLX-PAD<\/strong><span> was tested for Intermittent Claudication in a global, randomized, double-blind, placebo-controlled Phase II trial. PLX-PAD is a novel placenta-based cell therapy.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>FGF-1<\/strong><span> is being tested by <\/span><strong>Venturis Therapeutics (Cardiovascular Biotherapeutics)<\/strong><span> to treat Peripheral Artery Disease with Intermittent Claudication.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Discover more about the disease by requesting for sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intermittent-claudication-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Intermittent Claudication Pathophysiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Intermittent Claudication market report<\/strong><span> also examines current Intermittent Claudication treatment practices\/algorithms, Intermittent Claudication market drivers, Intermittent Claudication market barriers, and unmet medical needs to identify and evaluate the Intermittent Claudication market&#8217;s underlying potential.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Intermittent Claudication: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The most common manifestation of Peripheral Artery Disease is Intermittent Claudication, which is defined as activity-induced dysfunction and muscle pain (claudication pain) relieved by rest. The second stage of PAD is Intermittent Claudication, further subdivided into Stage IIa- claudication at a walking distance greater than 200 m and IIb- claudication at a distance of less than 200 m.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Intermittent Claudication Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The Intermittent Claudication report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Peripheral Artery Disease Total Prevalence&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Intermittent Claudication Prevalent Population<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Intermittent Claudication Gender-Specific Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Intermittent Claudication Diagnosed and Treatable Cases&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Intermittent Claudication Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The best recommendations for Intermittent Claudication treatment include <\/span><span>lifestyle changes<\/span><span> such as avoiding saturated fats, <\/span><span>not smoking or using tobacco<\/span><span>,<\/span><span> increasing physical activity, controlling cholesterol, blood sugar, and blood pressure to healthy levels, and maintaining a healthy weight<\/span><span> are the best recommendations. Medications to improve blood flow or lower the risk of blood clots are also advised. Some of the FDA-approved drugs that are used for Intermittent Claudication treatment include <\/span><span>Pentoxifylline, Pentoxil, Cilostazol, <\/span><span>and others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Intermittent Claudication Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>With an increase in the prevalence of Intermittent Claudication and the high demand for therapies, approval of emerging therapies such as <\/span><span>PLX-PAD, FGF-1<\/span><span>, and others via novel mechanisms will significantly boost the Intermittent Claudication therapy market size in the forecasted period (2021-2030).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get the overview about the emerging therapies @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intermittent-claudication-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Drugs used to treat Intermittent Claudication<\/a><\/strong><span>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Intermittent Claudication Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>PLX-PAD: Pluristem<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>FGF-1: Venturis Therapeutics, Inc.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><strong>Table of Contents<\/strong>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"61\" \/>\n<col width=\"563\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary of Intermittent Claudication&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Background and Overview: Intermittent Claudication&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Patient Journey<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Epidemiology and Patient Population&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication: Country-Wise Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Treatment and Medical Practices<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Prescribed Drug<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Key Emerging Therapies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication: Market Size<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>7MM Intermittent Claudication: Country-Wise Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>KOL view<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Intermittent Claudication Market Access and Reimbursement<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>21.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>22.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>23.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Peripheral Artery Disease Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Peripheral Artery Disease<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <strong>lucent<\/strong><\/span><strong>&nbsp;Medical Inc., AnGes MG Inc., Bayer AG, Betagenon AB, BiogenCell Ltd, Novartis AG, Reven Pharmaceuticals Inc.<\/strong><span><strong>,<\/strong>&nbsp;<\/span><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=emerging-therapies-such-as-plxpad-pluristem-fgf1-venturis-therapeutics-inc-and-others-expected-to-positively-impact-the-intermittent-claudication-market-scenario-in-the-upcoming-years\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=emerging-therapies-such-as-plxpad-pluristem-fgf1-venturis-therapeutics-inc-and-others-expected-to-positively-impact-the-intermittent-claudication-market-scenario-in-the-upcoming-years\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intermittent Claudication Market An increase in the prevalence of Intermittent Claudication and the high demand for therapies, approval of emerging therapies such as PLX-PAD, FGF-1, and others will significantly boost the Intermittent Claudication therapy market size in the forecasted period &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/emerging-therapies-such-as-plxpad-pluristem-fgf1-venturis-therapeutics-inc-and-others-expected-to-positively-impact-the-intermittent-claudication-market-scenario-in-the-upcoming-years_558437.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-558437","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/558437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=558437"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/558437\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=558437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=558437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=558437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}